Abstract
ObjectivePARADIGMS demonstrated superior efficacy and comparable safety of fingolimod versus interferon β-1a (IFN β-1a) in paediatric-onset multiple sclerosis (PoMS). This study aimed to report all predefined MRI outcomes from this...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have